WallStreetZenWallStreetZen

NASDAQ: MGTX
Meiragtx Holdings PLC Stock

$5.22-0.15 (-2.79%)
Updated Nov 30, 2023
MGTX Price
$5.22
Fair Value Price
$6.93
Market Cap
$331.98M
52 Week Low
$3.49
52 Week High
$8.77
P/E
-2.11x
P/B
3.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$131.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.91
Operating Cash Flow
-$107M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MGTX Overview

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MGTX ($5.22) is undervalued by 24.66% relative to our estimate of its Fair Value price of $6.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MGTX ($5.22) is significantly undervalued by 24.66% relative to our estimate of its Fair Value price of $6.93 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MGTX due diligence checks available for Premium users.

Be the first to know about important MGTX news, forecast changes, insider trades & much more!

MGTX News

Valuation

MGTX fair value

Fair Value of MGTX stock based on Discounted Cash Flow (DCF)
Price
$5.22
Fair Value
$6.93
Undervalued by
24.66%
MGTX ($5.22) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MGTX ($5.22) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MGTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.11x
Industry
12.22x
Market
29.24x

MGTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.61x
Industry
5.4x
MGTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MGTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$44.3M
Profit Margin
0%
MGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$267.2M
Liabilities
$175.3M
Debt to equity
1.91
MGTX's short-term assets ($103.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGTX's long-term liabilities ($111.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$24.4M
Investing
-$3.6M
Financing
-$404.0k
MGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MGTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MGTX$331.98M-2.79%-2.11x3.61x
GRCL$331.80M+7.51%-3.95x2.10x
TSHA$329.05M-3.30%-0.68x-6.70x
ITOS$334.95M-3.51%-5.44x0.56x
GHRS$324.61M+0.81%-7.93x1.44x

Meiragtx Holdings Stock FAQ

What is Meiragtx Holdings's quote symbol?

(NASDAQ: MGTX) Meiragtx Holdings trades on the NASDAQ under the ticker symbol MGTX. Meiragtx Holdings stock quotes can also be displayed as NASDAQ: MGTX.

If you're new to stock investing, here's how to buy Meiragtx Holdings stock.

What is the 52 week high and low for Meiragtx Holdings (NASDAQ: MGTX)?

(NASDAQ: MGTX) Meiragtx Holdings's 52-week high was $8.77, and its 52-week low was $3.49. It is currently -40.48% from its 52-week high and 49.57% from its 52-week low.

How much is Meiragtx Holdings stock worth today?

(NASDAQ: MGTX) Meiragtx Holdings currently has 63,597,151 outstanding shares. With Meiragtx Holdings stock trading at $5.22 per share, the total value of Meiragtx Holdings stock (market capitalization) is $331.98M.

Meiragtx Holdings stock was originally listed at a price of $15.00 in Jun 8, 2018. If you had invested in Meiragtx Holdings stock at $15.00, your return over the last 5 years would have been -65.2%, for an annualized return of -19.03% (not including any dividends or dividend reinvestments).

How much is Meiragtx Holdings's stock price per share?

(NASDAQ: MGTX) Meiragtx Holdings stock price per share is $5.22 today (as of Nov 30, 2023).

What is Meiragtx Holdings's Market Cap?

(NASDAQ: MGTX) Meiragtx Holdings's market cap is $331.98M, as of Dec 2, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Meiragtx Holdings's market cap is calculated by multiplying MGTX's current stock price of $5.22 by MGTX's total outstanding shares of 63,597,151.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.